MTEM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MTEM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Molecular Templates's annualized net income for the quarter that ended in Dec. 2023 was $-15.79 Mil. Molecular Templates's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $5.51 Mil. Therefore, Molecular Templates's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -286.79%.
The historical rank and industry rank for Molecular Templates's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, Molecular Templates's highest Return-on-Tangible-Equity was 519.53%. The lowest was -366.98%. And the median was -78.82%.
The historical data trend for Molecular Templates's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Templates Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -78.30 | -129.23 | -132.81 | -366.98 | - |
Molecular Templates Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Return-on-Tangible-Equity | Get a 7-Day Free Trial | - | Negative Tangible Equity | - | - | -286.79 |
For the Biotechnology subindustry, Molecular Templates's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Molecular Templates's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Molecular Templates's Return-on-Tangible-Equity falls into.
Molecular Templates's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -8.124 | / | ( (-15.132 | + | 4.212 ) | / 2 ) | |
= | -8.124 | / | -5.46 | ||||
= | N/A % |
Molecular Templates's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | -15.792 | / | ( (6.801 | + | 4.212) | / 2 ) | |
= | -15.792 | / | 5.5065 | ||||
= | -286.79 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
Molecular Templates (NAS:MTEM) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of Molecular Templates's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Maurizio Voi | officer: Chief Medical Officer | 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Sean Mclennan | officer: CFO & Treasurer | C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729 |
Kevin M. Lalande | director, 10 percent owner | 201 WEST 5TH STREET, AUSTIN TX 78701 |
Shv Management Services, Llc | 10 percent owner | FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701 |
Gabriela Gruia | director | C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Jason S. Kim | officer: See Remarks | 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729 |
Biotech Ag Bb | 10 percent owner | SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Sanders Corazon (corsee) D. | director | C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729 |
Patrick G Enright | 10 percent owner | CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Bakker Juliet Tammenoms | 10 percent owner | LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
David Hirsch | director, 10 percent owner | C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Longitude Venture Partners Iii, L.p. | 10 percent owner | 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Scott D Morenstein | director | C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By Value_Insider Value_Insider • 11-04-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 06-06-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By GlobeNewswire GlobeNewswire • 06-17-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 06-17-2023
By sperokesalga sperokesalga • 03-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.